RELAPSED/REFRACTORY SMALL CELL LUNG CANCER
Clinical trials for RELAPSED/REFRACTORY SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat lung cancer: experimental combo enters trials
Disease control Recruiting nowThis study tests a new drug called BMS-986525, given alone or with another drug (nivolumab), in people whose small cell lung cancer has come back or stopped responding to treatment. The main goals are to check safety and find the right dose. About 240 adults who have already had …
Matched conditions: RELAPSED/REFRACTORY SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New immune cell therapy takes on tough lung cancer
Disease control Recruiting nowThis early study tests a new treatment called GC511B for adults with a type of lung cancer that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CAR T cells) to target a protein called DLL3 on cancer cells. The main goals a…
Matched conditions: RELAPSED/REFRACTORY SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 13, 2026 15:58 UTC